Evidence map›Paper›PMID 25961742›Full record

ArticlePloS one2015

Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues.

Felipe Vaca-Paniagua, Rosa María Alvarez-Gomez, Hector Aquiles Maldonado-Martínez, Carlos Pérez-Plasencia, Veronica Fragoso-Ontiveros, Federico Lasa-Gonsebatt, Luis Alonso Herrera, David Cantú, Enrique Bargallo-Rocha, Alejandro Mohar and 10 more

Abstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Comparison ofJCO precision oncology · 2022
    Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. A Population of Heterogeneous Breast Cancer Patient-Derived Xenografts Demonstrate Broad Activity of PARP Inhibitor in BRCA1/2 Wild-Type Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Felipe Vaca-PaniaguaGroup of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon, France; Subdirección de Investigación Básica, Instituto Nacional de Cancerología, México D.F., México; Unidad de Biomedicina, FES-Iztacala, Universidad Nacional Autónoma de México (UNAM), México D.F., México.
Rosa María Alvarez-GomezUnidad de Genómica y Secuenciación Masiva (UGESEM), Instituto Nacional de Cancerología, México D.F., México.
Hector Aquiles Maldonado-MartínezDepartamento de Patología Molecular, Instituto Nacional de Cancerología, México D.F., México.
Carlos Pérez-PlasenciaSubdirección de Investigación Básica, Instituto Nacional de Cancerología, México D.F., México; Unidad de Biomedicina, FES-Iztacala, Universidad Nacional Autónoma de México (UNAM), México D.F., México; Unidad de Genómica y Secuenciación Masiva (UGESEM), Instituto Nacional de Cancerología, México D.F., México.
Veronica Fragoso-OntiverosSubdirección de Investigación Básica, Instituto Nacional de Cancerología, México D.F., México; Unidad de Genómica y Secuenciación Masiva (UGESEM), Instituto Nacional de Cancerología, México D.F., México.
Federico Lasa-GonsebattDepartamento de Epidemiología, Instituto Nacional de Cancerología, México D.F., México.
Luis Alonso HerreraUnidad de Investigaciones Biomédicas en Cáncer, Instituto Nacional de Cancerología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), México D.F., México.
David CantúUnidad de Investigaciones Biomédicas en Cáncer, Instituto Nacional de Cancerología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México (UNAM), México D.F., México.
Enrique Bargallo-RochaDepartamento de Tumores Mamarios, Instituto Nacional de Cancerología, México D.F., México.
Alejandro MoharDepartamento de Epidemiología, Instituto Nacional de Cancerología, México D.F., México.
Geoffroy DurandGroup of Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Nathalie ForeyGroup of Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Catherine VoegeleGroup of Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Maxime ValléeGroup of Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Florence Le Calvez-KelmGroup of Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
James McKayGroup of Genetic Cancer Susceptibility, International Agency for Research on Cancer, Lyon, France.
Maude ArdinGroup of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon, France.
Stéphanie VillarGroup of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon, France.
Jiri ZavadilGroup of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon, France.
Magali OlivierGroup of Molecular Mechanisms and Biomarkers, International Agency for Research on Cancer, Lyon, France.

Funding

World Health Organization 001
6 · The paper itself

Abstract

Triple negative breast cancer (TNBC), defined by the lack of expression of the estrogen receptor, progesterone receptor and human epidermal receptor 2, is an aggressive form of breast cancer that is more prevalent in certain populations, in particular in low- and middle-income regions. The detailed molecular features of TNBC in these regions remain unexplored as samples are mostly accessible as formalin-fixed paraffin embedded (FFPE) archived tissues, a challenging material for advanced genomic and transcriptomic studies. Using dedicated reagents and analysis pipelines, we performed whole exome sequencing and miRNA and mRNA profiling of 12 FFPE tumor tissues collected from pathological archives in Mexico. Sequencing analyses of the tumor tissues and their blood pairs identified TP53 and RB1 genes as the most frequently mutated genes, with a somatic mutation load of 1.7 mutations/exome Mb on average. Transcriptional analyses revealed an overexpression of growth-promoting signals (EGFR, PDGFR, VEGF, PIK3CA, FOXM1), a repression of cell cycle control pathways (TP53, RB1), a deregulation of DNA-repair pathways, and alterations in epigenetic modifiers through miRNA:mRNA network de-regulation. The molecular programs identified were typical of those described in basal-like tumors in other populations. This work demonstrates the feasibility of using archived clinical samples for advanced integrated genomics analyses. It thus opens up opportunities for investigating molecular features of tumors from regions where only FFPE tissues are available, allowing retrospective studies on the search for treatment strategies or on the exploration of the geographic diversity of breast cancer.

Indexed as

AdultFemaleFormaldehydeHumansIn Vitro TechniquesMiddle AgedParaffinRetrospective StudiesTissue FixationTriple Negative Breast NeoplasmsFormaldehydeParaffin

Identifiers

PMID25961742
PMCPMC4427337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.